Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo.
Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo.
复制标题
DOI:
10.1038/s41591-018-0165-9
复制
发表时间:
2018-11
期刊:
影响因子:
82.9
通讯作者:
Minczuk M
中科院分区:
文献类型:
--
作者:
Gammage PA;Viscomi C;Simard ML;Costa ASH;Gaude E;Powell CA;Van Haute L;McCann BJ;Rebelo-Guiomar P;Cerutti R;Zhang L;Rebar EJ;Zeviani M;Frezza C;Stewart JB;Minczuk M
Mutations of the mitochondrial genome (mtDNA) underlie a significant portion of mitochondrial disease burden. These disorders are currently incurable and effectively untreatable, with heterogeneous penetrance, presentation and prognosis. To address the lack of effective treatment for these disorders, we exploited a recently developed mouse model that recapitulates common molecular features of heteroplasmic mtDNA disease in cardiac tissue, the m.5024C>T tRNAALA mouse. Through application of a programmable nuclease therapy approach, using systemically administered, mitochondrially targeted zinc finger-nucleases (mtZFNs) delivered by adeno-associated virus, we induced specific elimination of mutant mtDNA across the heart, coupled to a reversion of molecular and biochemical phenotypes. These findings constitute proof-of-principle that mtDNA heteroplasmy correction using programmable nucleases could provide a therapeutic route for heteroplasmic mitochondrial diseases of diverse genetic origin.
登录
查看更多内容
影响因子:
11.2
作者:
Gorman GS;Schaefer AM;Ng Y;Gomez N;Blakely EL;Alston CL;Feeney C;Horvath R;Yu-Wai-Man P;Chinnery PF;Taylor RW;Turnbull DM;McFarland R
通讯作者:
McFarland R
影响因子:
14.9
作者:
Gammage PA;Gaude E;Van Haute L;Rebelo-Guiomar P;Jackson CB;Rorbach J;Pekalski ML;Robinson AJ;Charpentier M;Concordet JP;Frezza C;Minczuk M
通讯作者:
Minczuk M
DOI:
10.1073/pnas.0609502103
发表时间:
2006-12-26
影响因子:
11.1
作者:
Minczuk, Michal;Papworth, Monika A.;Klug, Aaron
通讯作者:
Klug, Aaron
影响因子:
4.7
作者:
Beilstein, Kim;Wittmann, Alexander;Suess, Beatrix
通讯作者:
Suess, Beatrix
影响因子:
64.8
作者:
通讯作者:
--